| First Author | Liao X | Year | 2020 |
| Journal | JCI Insight | Volume | 5 |
| Issue | 4 | PubMed ID | 32102983 |
| Mgi Jnum | J:324396 | Mgi Id | MGI:6753817 |
| Doi | 10.1172/jci.insight.135119 | Citation | Liao X, et al. (2020) Identification of Alzheimer's disease-associated rare coding variants in the ECE2 gene. JCI Insight 5(4) |
| abstractText | Accumulation of amyloid beta protein (Abeta) due to increased generation and/or impaired degradation plays an important role in Alzheimer's disease (AD) pathogenesis. In this report, we describe the identification of rare coding mutations in the endothelin-converting enzyme 2 (ECE2) gene in 1 late-onset AD family, and additional case-control cohort analysis indicates ECE2 variants associated with the risk of developing AD. The 2 mutations (R186C and F751S) located in the peptidase domain in the ECE2 protein were found to severely impair the enzymatic activity of ECE2 in Abeta degradation. We further evaluated the effect of the R186C mutation in mutant APP-knockin mice. Overexpression of wild-type ECE2 in the hippocampus reduced amyloid load and plaque formation, and improved learning and memory deficits in the AD model mice. However, the effect was abolished by the R186C mutation in ECE2. Taken together, the results demonstrated that ECE2 peptidase mutations contribute to AD pathogenesis by impairing Abeta degradation, and overexpression of ECE2 alleviates AD phenotypes. This study indicates that ECE2 is a risk gene for AD development and pharmacological activation of ECE2 could be a promising strategy for AD treatment. |
